Amyloidosis News - June 2021

hATTR risk can be identified through genomic screening and guide management early on, preventing potential diagnostic and treatment delays. Read More ›

Wild-type transthyretin amyloidosis remains a clinical challenge, exacerbated by diagnostic delays. Read More ›

Researchers evaluated patient characteristics that may be associated with positive technetium pyrophosphate uptake and aid in the diagnosis of cardiac transthyretin amyloidosis. Read More ›

Considerable cardiovascular disease burden is often seen in patients with hereditary transthyretin amyloidosis in the 5 years preceding diagnosis. Read More ›

A complete diagnostic workup is critical to ensure accurate subtyping, with the recognition that both transthyretin and light chain amyloidosis can occur concurrently. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.